-

Axonics® CEO Raymond W. Cohen Receives Lifetime Entrepreneurial Achievement Award by the Southern California Biomedical Council

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that Raymond W. Cohen, chief executive officer of Axonics, has been awarded the 2021 Lifetime Entrepreneurial Achievement Award by the Southern California Biomedical Council (SoCalBio).

“This award recognizes bioscience and healthcare entrepreneurs and change-makers in the greater Los Angeles/Orange County region,” said Robert Greenberg, M.D., Ph.D, chairman of SoCalBio and executive chairman of the Alfred Mann Foundation. “Mr. Cohen has excelled in creating innovative companies, providing high quality jobs, and bringing impactful and life-changing medical products to market. Mr. Cohen’s most recent venture, Axonics, embodies all these qualities and manifests a vision that fosters innovation, growth and community prosperity.”

SoCalBio is a non-profit trade association that supports research, development, manufacturing, job creation and overall economic growth in the greater Los Angeles/Orange County region. Mr. Cohen was selected to receive the SoCalBio Lifetime Entrepreneurial Achievement Award by the executive committee of the SoCalBio board of directors and by members of the organization’s Innovation Catalyst Program.

“It is an honor to receive the SoCalBio 2021 Lifetime Entrepreneurial Achievement Award,” said Raymond W. Cohen. “Entrepreneurs play a vital role in job creation and driving innovation. My journey over the past four decades in the life science industry has been extremely gratifying. A key learning for me has been that the ‘tone from the top’ is crucial to establishing company cultures where integrity, diversity, authenticity, teamwork and quality are highly valued and rewarded.”

Mr. Cohen continued, “Leading Axonics since its founding in late 2013 has been a privilege. In particular, I am proud that we manufacture our products in Irvine and provide high quality jobs in the community. I share this recognition with the 550 dedicated employees at Axonics that are keenly focused on improving the lives of patients suffering from bladder and bowel dysfunction.”

About Axonics

Based in Irvine, Calif., Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. The company’s rechargeable sacral neuromodulation (SNM) system provides patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, Axonics’ best-in-class urethral bulking agent, Bulkamid®, provides safe and durable symptom relief to women with stress urinary incontinence (SUI).

Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. SUI affects an estimated 20 million women in the U.S. alone. Axonics’ clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit www.axonics.com.

Contacts

Axonics contact:
Neil Bhalodkar
Investor Relations
949-336-5293
ir@axonics.com

Axonics, Inc.

NASDAQ:AXNX

Release Versions

Contacts

Axonics contact:
Neil Bhalodkar
Investor Relations
949-336-5293
ir@axonics.com

Social Media Profiles
More News From Axonics, Inc.

Axonics Reports Third Quarter 2024 Financial Results

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a medical technology company that develops, manufactures and commercializes innovative and minimally invasive products to treat bladder and bowel dysfunction, today reported financial results for the three months ended September 30, 2024. “Axonics continued to execute at a high level in the third quarter, generating revenue growth of 25% year over year,” said Raymond W. Cohen, chief executive officer. “Revenue growth for both sacral...

Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in Australia

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that it has received regulatory approval from the Therapeutic Goods Administration (TGA) for marketing the Axonics R20® rechargeable sacral neuromodulation (SNM) system in Australia to treat adults with overactive bladder and fecal incontinence. The R20 neurostimulator is labeled for a functional life in the body of at least 20 years and reduces how frequently a patient needs to recharge their implanted device to once...

Axonics Prevails in Patent Infringement Lawsuit with Medtronic

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that the jury has returned a unanimous verdict in the patent infringement lawsuit brought by Medtronic against Axonics in U.S. District Court for the Central District of California. The jury found that Axonics does not infringe any of the three patents-in-suit. “A jury of our peers recognized that Axonics’ proprietary tined lead design and temperature sensor technology is differentiated from our competitor’s intellect...
Back to Newsroom